<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05795816</url>
  </required_header>
  <id_info>
    <org_study_id>FENCOV</org_study_id>
    <nct_id>NCT05795816</nct_id>
  </id_info>
  <brief_title>Effectiveness of Testofen Compared to Placebo on Long COVID Symptoms</brief_title>
  <official_title>The Effectiveness of Testofen on Energy, Fatigue, Mental Acuity, and Other Quality of Life Symptoms Post COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RDC Clinical Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RDC Clinical Pty Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed&#xD;
      Testofen (a specialised extract of Trigonella foenum-graecum (Fenugreek) seed) compared to&#xD;
      placebo on post COVID-19 symptoms in otherwise healthy participants 18 years and over.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2023</start_date>
  <completion_date type="Anticipated">August 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Energy and Fatigue</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>Change in energy and fatigue as measured via Fatigue Severity Scale. The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Energy and Fatigue</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>Change in energy and fatigue as measured via Global Fatigue Index. The items are scored on a 10 point scale with 1 = not at all and 10 = great deal. Higher he score = greater fatigue</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Memory</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>Change in Memory as measured by Short Term Memory testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mental Acuity</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>Change in Mental acuity as measured by Reaction Time Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Muscle Strength (Hand grip)</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>Change in Muscle Strength (Hand grip) as measured by Dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hair loss/growth</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>Change in Hair loss/growth as measured by Hair loss questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Libido</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>Change in Libido as measured by - If male, DISF-SR (Derogatis Sexual Function Index), If female, FSFI (Female Sexual Function Index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stress and Mood</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>Change in Stress and Mood via Depression Anxiety and Stress Scale (DASS-21)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Indicators</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>Change in Quality of Life Indicators via Symptom Burden Questionnaire - Long Covid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pathology results via Blood test</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>Change in Pathology results (Full blood count (including platelet aggregation), Soluble P-selectin, Testosterone, DHT, SHBG, Estrogen, IGF1, Cortisol, Prostaglandins, Inflammatory markers IL-10, IL-6, IL-17, TNF-a) as measured by Blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>Change in Weight as measured by scales in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>Height as measured by tape measure in centimetres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Safety as assessed by Adverse Events Recording</measure>
    <time_frame>During enrolment period</time_frame>
    <description>Change in Safety as assessed by Adverse Events Recording</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in safety markers as assessed by pathology</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>Change in safety markers E/LFT as assessed by pathology</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Long Covid19</condition>
  <arm_group>
    <arm_group_label>Testofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testofen in capsule form - taken as 2 x 300 mg daily with food (1 in the morning and 1 in the evening)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microcrystalline cellulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microcrystalline cellulose in capsule form - taken as 2 x 300 mg daily with food (1 in the morning and 1 in the evening)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testofen</intervention_name>
    <description>Twice daily dose of 1 capsule (300mg per capsule Testofen)</description>
    <arm_group_label>Testofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microcrystalline cellulose</intervention_name>
    <description>Twice daily dose of 1 capsule (300mg per capsule)</description>
    <arm_group_label>Microcrystalline cellulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults 18 years and over&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Diagnosed with COVID-19 infection (RAT or PCR test) &gt;4 weeks, but &lt; 12 months and&#xD;
             experiencing post COVID symptoms (1)&#xD;
&#xD;
          -  Agree not to participate in another clinical trial while enrolled in this trial&#xD;
&#xD;
               1. Common post COVID symptoms may include fatigue, cough, chest pain, hair loss,&#xD;
                  weakness, joint pain, cardiac issues, neurocognitive impairment including memory&#xD;
                  loss, and decreased quality of life&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptoms resulting from vaccination (2)&#xD;
&#xD;
          -  Unstable or serious illness (e.g., serious mood disorders, neurological disorders such&#xD;
             as MS, kidney disease, liver disease, heart conditions, diabetes, thyroid gland&#xD;
             dysfunction) (3)&#xD;
&#xD;
          -  Current malignancy (excluding BCC) or chemotherapy and radiotherapy treatment for&#xD;
             malignancy within the previous 2 years&#xD;
&#xD;
          -  Receiving/prescribed coumandin (Warfarin), heparin, dalteaparin, enoxaparin or other&#xD;
             anticoagulation therapy&#xD;
&#xD;
          -  Receiving pharmaceutical treatment for anxiety, libido, low energy&#xD;
&#xD;
          -  Active smokers, nicotine use, alcohol, or drug (prescription or illegal substances)&#xD;
             abuse&#xD;
&#xD;
          -  Chronic past and/or current alcohol use (&gt;14 alcoholic drinks per week)&#xD;
&#xD;
          -  Allergic to any of the ingredients in the active or placebo formula&#xD;
&#xD;
          -  Known pregnant or lactating women&#xD;
&#xD;
          -  Any condition which in the opinion of the investigator makes the participant&#xD;
             unsuitable for inclusion&#xD;
&#xD;
          -  Participants who have participated in any other related clinical study during the past&#xD;
             1 month&#xD;
&#xD;
          -  History of infection in the month prior to the study&#xD;
&#xD;
             (2) Symptoms must be as a direct result of having contracted COVID. If symptoms only&#xD;
             appeared within 2 weeks of a vaccination it will be considered a vaccine injury and&#xD;
             not classed as a result of COVID.&#xD;
&#xD;
             (3) An unstable illness is any illness that is currently not being treated with a&#xD;
             stable dose of medication or is fluctuating in severity. A serious illness is a&#xD;
             condition that carries a risk of mortality, negatively impacts quality of life and&#xD;
             daily function and/or is burdensome in symptoms and/or treatments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda Rao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RDC Clinical Pty Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Rao, PhD</last_name>
    <phone>+61 414 488 559</phone>
    <email>amanda@rdcglobal.com.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Briskey, PhD</last_name>
    <phone>+61 421 784 077</phone>
    <email>david@rdcglobal.com.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RDC Clinical Pty Ltd</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Amanda Rao, PhD</last_name>
      <phone>+61 414 488 559</phone>
      <email>amanda@rdcglobal.com.au</email>
    </contact>
    <contact_backup>
      <last_name>David Briskey, PhD</last_name>
      <phone>+61 421 784 077</phone>
      <email>david@rdcglobal.com.au</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 27, 2023</study_first_submitted>
  <study_first_submitted_qc>March 30, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 30, 2023</last_update_submitted>
  <last_update_submitted_qc>March 30, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

